首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling

【24h】

TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling

机译：TAS-121是一种高效且突变特异性的EGFR抑制剂，通过特异性抑制突变EGFR信号传导，克服了T790M获得的耐药性，并具有有希望的抗肿瘤活性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2014年第6期|共1页
作者
Kato M.; Miyadera K.; Ito K.; Aoyagi Y.; Hashimoto A.; Yonekura K.; Iwasawa Y.; Utsugi T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling [J] . Kato M., Miyadera K., Ito K., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：TAS-121是一种高效且突变特异性的EGFR抑制剂，通过特异性抑制突变EGFR信号传导，克服了T790M获得的耐药性，并具有有希望的抗肿瘤活性
3. BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer [J] . Fushun Fan, Minhua Zhou, Xiaolan Ye, Translational Oncology . 2021,第2期

机译：BEBT-109，一种泛突变体 - 选择性EGFR抑制剂，具有高效抗肿瘤活性在EGFR-突变体非小细胞肺癌中
4. TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X [J] . Ito Kimihiro, Nishio Makoto, Kato Masanori, Molecular cancer therapeutics . 2019,第5期

机译：Tas-121，一种选择性突变型EGFR抑制剂，显示出对表达各种EGFR突变的肿瘤的活性，包括T790M和罕见突变G719x
5. Proteomic analyses of EGFR-interacting proteins to elucidate differences in signal transduction downstream of lung cancer-specific mutant EGFRs [C] . Udayan Guha, Todd M. Greco, Abhilash Venugopalan, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：EGFR-相互作用蛋白的蛋白质组学分析，以阐明肺癌特异性突变蛋白的信号转导差异
6. Exploitation and mechanistic validation of drug-combination strategies to overcome EGFR-inhibitor resistance in NSCLC cells [D] . Wang, Yu-Chieh. 2008

机译：克服NSCLC细胞中EGFR抑制剂耐药性的药物联合策略的开发和机理验证
7. Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance [O] . Takeshi Shimamura, Danan Li, Hongbin Ji, -1

机译：Hsp90抑制抑制突变的EGFR-T790M信号并克服激酶抑制剂的耐药性
8. Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance [O] . Takeshi Shimamura, Danan Li, Hongbin Ji, 2008

机译：HSP90抑制抑制突变体EGFR-T790M信号传导并克服激酶抑制剂抗性

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号